Admittedly the concern is from an in vitro study. Authors conclude risk "is not zero." Merck defends itself.Michael Lerner With heightened excitement centering on the recent announcement by Merck that its investigational antiviral therapy molnupiravir reduces the...
By Di Pierro F, et al. Published June 24, 2021 in the International Journal of General Medicine Abstract Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing global pandemic known as COVID-19. Based on the potential...
Merck’s molnupiravir has certainly received a lot of good press over the past days since the New Jersey-based pharmaceutical company announced its clinical trial demonstrates positive results. They will be expeditiously working to file for an emergency use...
By Kathleen Doheny Soon after Merck announced on October 1 that it would ask federal regulators for emergency use authorization (EUA) for its auspicious new COVID-19 pill, the accolades began. Former US Food and Drug Administration (FDA) chief Scott...
Merck’s recent announcement about Molnupiravir indicates the possible imminence of an orally administered antiviral medication targeting COVID-19. The market for this drug class is substantial, given that about 90% of COVID-19 patients fall in the mild-to-moderate...
— But enrollment halted early, and few patients were actually hospitalized by Molly Walker Remdesivir (Veklury) reduced risk of hospitalizations by 87% compared with placebo in outpatients at high risk of progression to severe COVID-19, a researcher said. While the...
By JoNel Aleccia Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to...
Championed by doctors and conservative radio hosts alike, monoclonal antibodies for Covid are in high demand — even from those who don’t want a vaccine. By Benjamin Mueller Lanson Jones did not think that the coronavirus would come for him. An avid tennis player in...
Dexamethasone Many doctors, including those in the United States, have been treating very ill COVID-19 patients with corticosteroids since the pandemic began. It makes biologic sense for those patients who have developed a hyper-immune response (a cytokine storm) to...
by Deep Shukla Acute respiratory distress syndrome (ARDS) is a potentially fatal condition involving lung damage, and experts often associate it with severe COVID-19.There is a link between high mortality rates and COVID-19-induced ARDS, which is why there is an...
By Gilmar Reis, et al. PREPRINT August 23, 2021 ABSTRACT Background Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER randomized platform clinical trial for acutely symptomatic patients with COVID-19, we assessed...
TrialSite has written extensively about the need for antiviral-type, early-care treatments targeting COVID-19. Early in the pandemic, this platform tracked numerous studies involving repurposed drugs such as ivermectin, favipiravir, hydroxychloroquine, and more. By...
Solidarity PLUS trial for promising drugs will roll out in 52 countries, an unprecedented global collaboration for COVID-19 R&D The World Health Organization (WHO) has announced the next phase in its Solidarity trial: Solidarity PLUS will enroll hospitalized...
A multinational, multi-site team of researchers led by Peter Jüni of St. Michael’s Hospital and the University of Toronto in Canada investigated the efficacy of heparin as a treatment for moderate to severe SARS-CoV-2 infection, the virus behind the COVID-19 pandemic....
Combining tocilizumab and sarilumab along with corticosteroids reduced the risk of death by 17% compared with corticosteroids alone. CIDRAP: WHO Advises 2 Monoclonal Antibodies For Severe COVID The World Health Organization (WHO) today recommended the use of...